MFS Blended Research International Equity Fund

MFS SERIES TRUST IV · 9 share classes

Actively managed developed international equity fund
One fund, 9 share classes:BRXAXBRXBXBRXCXBRXIXBRXRXBRXSXBRXTXBRXUXBRXVX
$4.79B NAV
171 positions · as of 2026-05-31 · filed 2026-07-27

Fund classification

Classified from what the fund holds · as of 2026 Q2

MFS Blended Research International Equity Fund is an actively managed developed international equity fund.

Asset class
Equity
Region
Developed international
Management
Actively managed
Fund type
Open-end fund

Fund profile

As filed in the prospectus · 2025 Q4

The funds investment objective is to seek capital appreciation.

Strategy · summarised

The fund actively selects foreign equity securities across all market capitalizations and geographies using a blend of fundamental and quantitative analysis, then optimizes the portfolio against the MSCI All Country World (ex-US) Index with a target tracking error of approximately 2%. Because the fund constructs its portfolio through optimization rather than index replication, its returns may diverge from the benchmark. The fund normally holds at least 80% of assets in equities and may concentrate a significant portion in a single industry, sector, country, or region.

Expenses
0.44% 1.52%across 9 share classes
Share classGrossNet
BRXAX0.78%0.77%
BRXBX1.53%1.52%
BRXCX1.53%1.52%
BRXIX0.53%0.52%
BRXRX1.53%1.52%
BRXSX1.03%1.02%
BRXTX0.78%0.77%
BRXUX0.53%0.52%
BRXVX0.45%0.44%

Net is what a holder pays after the adviser's contractual waiver; gross is before it. A waiver can expire.

Portfolio turnover 48.00% · as of 2025 Q4

Allocation

Asset groups · long / short shown separately, never netted · 2026 Q2

99.51%
of net assets
Stocks98.73%
Cash & short-term0.72%
Other0.06%

Derivatives are shown at market value, not notional exposure.

Latest quarter

What changed since the fund's previous filing

2026Q2 vs 2026Q1: 19 new16 exited

Largest new: AIB Group PLC, GSK PLC, Recruit Holdings Co Ltd, Roche Holding AG, Astellas Pharma Inc, ITOCHU Corp, Japan Airlines Co Ltd, Suzuki Motor Corp

Largest exited: Roche Holding AG, Kao Corp, Kirin Holdings Co Ltd, Alibaba Group Holding Ltd, Fresenius Medical Care AG, Sampo Oyj, Banco Santander SA, BYD Co Ltd

Return profile

Chart:

Total return as filed — price change plus distributions reinvested · trailing figures to Apr 2026

Share class1-year3-year5-yearVolWorst fall
+38.56%+78.30%+74.19%14.30%-10.18%
+37.53%+74.50%+67.60%14.30%-10.29%
+37.58%+74.52%+67.69%14.26%-10.32%
+38.88%+79.66%+76.20%14.27%-10.13%
+37.55%+74.38%+67.62%14.27%-10.32%
+38.24%+77.00%+71.79%14.30%-10.15%
+38.59%+78.44%+73.99%14.25%-10.12%
+38.92%+79.75%+76.26%14.27%-10.12%
+39.09%+80.14%+77.02%14.29%-10.04%

These classes hold the same portfolio, so the 9.42pp spread over 5 years is the cost difference between them — roughly 1.88pp a year — not a difference in what they own.

Cumulative return· Jun 2023 – Apr 2026

May 2026 has been filed since the trailing figures were struck, so it is not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.

Holdings

By % of NAV · equity positions carry filed share counts · every resolvable issuer links to its company page

Issuer%NAVValue
Taiwan Semiconductor Manufacturing Co LtdTSM4.84%$232.05M
SK hynix Inc3.81%$182.63M
Samsung Electronics Co Ltd2.77%$132.53M
ASML Holding NV2.41%$115.41M
Lenovo Group Ltd1.75%$84.05M
Novartis AG1.67%$79.96M
BNP Paribas SA1.55%$74.27M
Rio Tinto PLC1.49%$71.12M
Tencent Holdings Ltd1.47%$70.21M
UBS Group AG1.42%$68.00M
Showing 10 of 171Sign in to see more

Reported price is the fund's own reported value divided by its own reported shares at 2026-05-31 — not a live quote, and not what the fund paid.

Top 10 positions are 23.18% of net assets, top 25 40.15%, across 170 issuers.

See more of this fund's book

More positions with filed share counts, and the quarter-over-quarter change list rather than the largest few — free with an account, no card required.

Sign in free